3 Vanguard Mutual Funds That Can Weather Market Uncertainty
Vanguard slashes fees across 87 funds, and funds like VASVX, VWELX and VQNPX are poised to shine in a volatile, high-rate market.
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to persons ...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to ...
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due ...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million ( previously $180 million - $200 million ) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 ( previously $6.00 - $6.25 )
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week ( July 28-August 1 ) : Are The Others In Your Portfolio? - ATI ( NYSE:ATI ) , Baxter Intl ( NYSE:BAX )
Novo Nordisk plunged 31% after slashing its 2025 sales outlook. UPS, Moderna, and Coinbase dropped on weak Q2 results and guidance. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday. These ten large-cap stocks were the worst performers ...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Johnson & Johnson ( NYSE:JNJ ) , Baxter Intl ( NYSE:BAX )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Baxter ( BAX ) Q2 Revenue Rises 4%
Baxter International ( NYSE:BAX ) , a leading global provider of medical products and connected care solutions, released its second-quarter earnings on July 31, 2025. The company reported GAAP revenue of $2.81 billion and adjusted earnings per share ( EPS ) of $0.59, both just shy of consensus ...
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Medtronic ( NYSE:MDT )
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement
Baxter International ( BAX ) Misses Q2 Earnings and Revenue Estimates
Baxter (BAX) delivered earnings and revenue surprises of -1.67% and -0.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down
Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.
Stay Ahead of the Game With Baxter ( BAX ) Q2 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
InMode ( INMD ) Q2 Earnings and Revenues Beat Estimates
InMode (INMD) delivered earnings and revenue surprises of +9.30% and +0.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?
BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., July 24, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m.
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
Ligand to Report Second Quarter 2025 Financial Results on August ...
4 Mid-Cap Value Mutual Funds for Long-Term Gains
VASVX, TAMVX, TRVPX and FVLKX offer mid-cap value exposure with solid returns, low fees, and long-term growth potential.
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
Ligand Partner Pelthos Therapeutics Launches ...
Patient Handling Equipment Market Lifts Off: Valued at US$18.98 Billion, Poised for Strong Growth | AnalystView Market Insights
San Francisco, USA, July 02, 2025 ( GLOBE NEWSWIRE ) -- The patient handling equipment market is witnessing robust growth, valued at USD 18,987.65 million in 2024 and projected to grow at a compound annual growth rate ( CAGR ) of 6.7% from 2024 to 2032.
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - Ligand Pharmaceuticals ( NASDAQ:LGND )
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI
FMS Stock Likely to Gain on New Optimization Plan FME Reignite
Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.
Infusion Pump Market is expected to generate a revenue of USD 24.09 Billion by 2031, Globally, at 6% CAGR: Verified Market Research®
Lewes, Delaware, June 23, 2025 ( GLOBE NEWSWIRE ) -- The Global Infusion Pump Market Size is projected to grow at a CAGR of 6% from 2024 to 2031, according to a new report published by Verified Market Research®.
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
MD&M East Explores AI and Automation Shaping the Future of Manufacturing and MedTech
MD&M East Explores AI and Automation Shaping the Future of Manufacturing and ...
Spectral Medical Announces First Quarter and Provides Corporate Update
TORONTO, May 09, 2025 ( GLOBE NEWSWIRE ) -- Spectral Medical Inc. ( "Spectral" or the "Company" ) ( TSX: EDT ) , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter and provided a corporate update.
Looking Into Baxter Intl's Recent Short Interest - Baxter Intl ( NYSE:BAX )
Baxter Intl's BAX short percent of float has fallen 4.88% since its last report. The company recently reported that it has 17.27 million shares sold short, which is 5.07% of all regular shares that are available for trading.
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts. Shares rise in pre-market.
Baxter Reports Strong Medical Devices Sales In Q1, Lifts 2025 Guidance, Stock Jumps - Baxter Intl ( NYSE:BAX )
Baxter's Q1 adjusted EPS of $0.62 topped guidance of $0.47-$0.50 and beat the Street estimate of $0.48. Sales rose 5% to $2.63 billion, exceeding Baxter's forecast and $2.59B consensus. Today's manic market swings are creating the perfect setup for Matt's next volatility trade.
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 01, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) today announced that its senior management team will participate in the following upcoming investor conferences: • H.C. Wainwright Royalty Company Conference ( Virtual ) .
Ligand to Participate in May Investor Conferences - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., May 01, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference ( Virtual ) .
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies to report earnings on May 1, stay tuned!
Will BAX's Q1 Earnings Improve Following Transformation Completion?
Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.
What Does the Market Think About Baxter Intl? - Baxter Intl ( NYSE:BAX )
Baxter Intl's BAX short percent of float has risen 13.65% since its last report. The company recently reported that it has 18.16 million shares sold short, which is 5.33% of all regular shares that are available for trading.
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Channel Therapeutics ( AMEX:CHRO )
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™
BAX Stock Declines Despite Latest Product Launch Boosting Patient Care
Baxter aims to promote enhanced patient care through the evolution of its latest product, which enables direct accessibility in the operating room.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Prefilled Syringes Market Size to Reach US$ 15.00 Billion by 2030, Driven by Increasing Prevalence of Chronic Diseases - The Insight Partners
US & Canada, March 28, 2025 ( GLOBE NEWSWIRE ) -- US & Canada, Mar, 21, 2025 ( GlobeNewswire ) -- According to a comprehensive report from The Insight Partners, "Prefilled Syringe Market Size and Forecasts ( 2022 - 2030 ) , Global and Regional Share, Trends, and Growth Opportunity Analysis ...
Peering Into Baxter Intl's Recent Short Interest - Baxter Intl ( NYSE:BAX )
Baxter Intl's BAX short percent of float has fallen 12.66% since its last report. The company recently reported that it has 18.33 million shares sold short, which is 4.69% of all regular shares that are available for trading.
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update
154 patients enrolled 154 patients enrolled ...
Intravenous Equipment Market is Projected US$ 35,2670 Million, Expanding at 5.9% CAGR by 2035 | Fact.MR Analysis
Rockville, MD, March 20, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global intravenous ( IV ) equipment market is estimated to reach a valuation of US$ 19,881 million in 2025 and is expected to grow at a CAGR of 5.9% during the ...
Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader - Dentsply Sirona ( NASDAQ:XRAY )
CHARLOTTE, N.C., March 17, 2025 ( GLOBE NEWSWIRE ) -- DENTSPLY SIRONA Inc. ( "Dentsply Sirona" or the "Company" ) ( XRAY ) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025.
Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader
CHARLOTTE, N.C., March 17, 2025 ( GLOBE NEWSWIRE ) -- DENTSPLY SIRONA Inc. ( "Dentsply Sirona" or the "Company" ) ( XRAY ) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025.
Water for Injection Market Sales to Hit US$ 71.7 Billion by 2035, Boosted by Increasing Demand for High-Purity Water in Healthcare - Latest Report by TMR
Wilmington, Delaware, Transparency Market Research Inc. - , March 14, 2025 ( GLOBE NEWSWIRE ) -- The rising demand for high-purity water in pharmaceutical manufacturing and biotechnology is driving market growth.
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday - Baxter Intl ( NYSE:BAX ) , Airbnb ( NASDAQ:ABNB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays raised Baxter International Inc. BAX price target from $39 to $41.
Baxter Stock Likely to Gain Following the Introduction of Voalte Linq
At the 2025 HIMSS Global Healthcare Conference, BAX unveils its Voalte Linq device, powered by Scotty assistant, a voice-activated technology.
Starbucks Brews A New CFO: Taps Nordstrom Executive Cathy Smith Amid Organizational Changes - Starbucks ( NASDAQ:SBUX )
Ms. Smith's previous experience includes major roles at Nordstrom, Target. To join Starbucks, Ms. Smith will receive a cash signing bonus of $5 million. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades today.
Ligand to Participate in March Investor Conferences - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., March 03, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences:
Company News for Feb 21, 2025
Companies in The News Are: ...
